MedTrace Logo

Spike-specific Cellular Immune Response After COVID-19 Vaccination

NCT05102669 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2024-04-10

No results posted yet for this study

Summary

Aim of this study is to evaluate whether COVID-19 vaccination induces a persistent cellular immune response.

To this aim, blood samples are taken from vaccinated individuals and not immunized subjects as a control group.

Cells isolated from blood samples are tested in vitro to assess the percentage of spike-specific T and B lymphocytes 1 and 7 months after a second dose of Comirnaty vaccine.

Conditions

  • COVID19
  • Vaccination
  • Immune Response

Interventions

OTHER

analysis of immunological response

collection and analysis of SARS-CoV2 Spike specific blood cells

DIAGNOSTIC_TEST

analysis of serum antibodies

analysis of anti-SARS-CoV2 Spike specific antibodies

Sponsors & Collaborators

  • IRCCS San Raffaele Roma

    lead OTHER

Principal Investigators

  • Laura Vitiello, PhD · IRCCS San Raffaele Roma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-12
Primary Completion
2021-10-01
Completion
2021-10-11

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05102669 on ClinicalTrials.gov